ID   KS6B1_HUMAN             Reviewed;         525 AA.
AC   P23443; B2R779; B4DLT4; B4DTG1; E7ESB8; F6UYM1; Q7Z721;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 2.
DT   12-OCT-2022, entry version 221.
DE   RecName: Full=Ribosomal protein S6 kinase beta-1;
DE            Short=S6K-beta-1;
DE            Short=S6K1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:17936702, ECO:0000269|PubMed:18952604, ECO:0000269|PubMed:19085255, ECO:0000269|PubMed:28178239};
DE   AltName: Full=70 kDa ribosomal protein S6 kinase 1;
DE            Short=P70S6K1;
DE            Short=p70-S6K 1;
DE   AltName: Full=Ribosomal protein S6 kinase I;
DE   AltName: Full=Serine/threonine-protein kinase 14A;
DE   AltName: Full=p70 ribosomal S6 kinase alpha;
DE            Short=p70 S6 kinase alpha;
DE            Short=p70 S6K-alpha;
DE            Short=p70 S6KA;
GN   Name=RPS6KB1; Synonyms=STK14A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA I AND ALPHA II), AND ALTERNATIVE
RP   INITIATION.
RX   PubMed=1922062; DOI=10.1128/mcb.11.11.5541-5550.1991;
RA   Grove J., Bonerjee P., Balasubramanyam A., Coffer P., Price D.J.,
RA   Avruch J., Woodgett J.R.;
RT   "Cloning and expression of two human p70 S6 kinase polypeptides differing
RT   only at their amino termini.";
RL   Mol. Cell. Biol. 11:5541-5550(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS ALPHA I; 2 AND 4).
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=9804755; DOI=10.1074/jbc.273.46.30061;
RA   Gout I., Minami T., Hara K., Tsujishita Y., Filonenko V., Waterfield M.D.,
RA   Yonezawa K.;
RT   "Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6
RT   kinase beta containing a proline-rich region.";
RL   J. Biol. Chem. 273:30061-30064(1998).
RN   [7]
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-252, AND MUTAGENESIS OF
RP   THR-412; SER-434; SER-441; THR-444 AND SER-447.
RX   PubMed=9445476; DOI=10.1126/science.279.5351.707;
RA   Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C.,
RA   Hemmings B.A., Thomas G.;
RT   "Phosphorylation and activation of p70s6k by PDK1.";
RL   Science 279:707-710(1998).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF EEF2K, AND FUNCTION IN TRANSLATION
RP   REGULATION.
RX   PubMed=11500364; DOI=10.1093/emboj/20.16.4370;
RA   Wang X., Li W., Williams M., Terada N., Alessi D.R., Proud C.G.;
RT   "Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.";
RL   EMBO J. 20:4370-4379(2001).
RN   [9]
RP   INTERACTION WITH RPTOR.
RX   PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4;
RA   Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S.,
RA   Tokunaga C., Avruch J., Yonezawa K.;
RT   "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR
RT   action.";
RL   Cell 110:177-189(2002).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH TRAF4.
RX   PubMed=12801526; DOI=10.1016/s0145-2126(02)00325-9;
RA   Fleckenstein D.S., Dirks W.G., Drexler H.G., Quentmeier H.;
RT   "Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding
RT   partner for the p70S6 serine/threonine kinase.";
RL   Leuk. Res. 27:687-694(2003).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH POLDIP3.
RX   PubMed=15341740; DOI=10.1016/j.cub.2004.08.061;
RA   Richardson C.J., Broenstrup M., Fingar D.C., Julich K., Ballif B.A.,
RA   Gygi S., Blenis J.;
RT   "SKAR is a specific target of S6 kinase 1 in cell growth control.";
RL   Curr. Biol. 14:1540-1549(2004).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF EIF4B.
RX   PubMed=15071500; DOI=10.1038/sj.emboj.7600193;
RA   Raught B., Peiretti F., Gingras A.C., Livingstone M., Shahbazian D.,
RA   Mayeur G.L., Polakiewicz R.D., Sonenberg N., Hershey J.W.;
RT   "Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is
RT   modulated by S6 kinases.";
RL   EMBO J. 23:1761-1769(2004).
RN   [13]
RP   FUNCTION IN CELL CYCLE PROGRESSION.
RX   PubMed=14673156; DOI=10.1128/mcb.24.1.200-216.2004;
RA   Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., Blenis J.;
RT   "mTOR controls cell cycle progression through its cell growth effectors
RT   S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.";
RL   Mol. Cell. Biol. 24:200-216(2004).
RN   [14]
RP   FUNCTION IN TRANSLATION INITIATION, INTERACTION WITH EIF3B AND EIF3C, AND
RP   MUTAGENESIS OF THR-412.
RX   PubMed=16286006; DOI=10.1016/j.cell.2005.10.024;
RA   Holz M.K., Ballif B.A., Gygi S.P., Blenis J.;
RT   "mTOR and S6K1 mediate assembly of the translation preinitiation complex
RT   through dynamic protein interchange and ordered phosphorylation events.";
RL   Cell 123:569-580(2005).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF GSK3B.
RX   PubMed=17052453; DOI=10.1016/j.molcel.2006.09.019;
RA   Zhang H.H., Lipovsky A.I., Dibble C.C., Sahin M., Manning B.D.;
RT   "S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition
RT   of Akt.";
RL   Mol. Cell 24:185-197(2006).
RN   [16]
RP   FUNCTION.
RX   PubMed=17053147; DOI=10.1126/science.1130276;
RA   Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H.,
RA   Sherman N.E., Pagano M.;
RT   "S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein
RT   translation and cell growth.";
RL   Science 314:467-471(2006).
RN   [17]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF LYS-167 AND SER-394.
RX   PubMed=17446865; DOI=10.1038/sj.emboj.7601682;
RA   Hauge C., Antal T.L., Hirschberg D., Doehn U., Thorup K., Idrissova L.,
RA   Hansen K., Jensen O.N., Jorgensen T.J., Biondi R.M., Frodin M.;
RT   "Mechanism for activation of the growth factor-activated AGC kinases by
RT   turn motif phosphorylation.";
RL   EMBO J. 26:2251-2261(2007).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF URI1, CATALYTIC ACTIVITY, DEPHOSPHORYLATION
RP   AT THR-412 BY PPP1CC, AND SUBCELLULAR LOCATION.
RX   PubMed=17936702; DOI=10.1016/j.molcel.2007.08.010;
RA   Djouder N., Metzler S.C., Schmidt A., Wirbelauer C., Gstaiger M.,
RA   Aebersold R., Hess D., Krek W.;
RT   "S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes
RT   activates a negative feedback program that counters S6K1 survival
RT   signaling.";
RL   Mol. Cell 28:28-40(2007).
RN   [19]
RP   PHOSPHORYLATION AT THR-412.
RX   PubMed=18925875; DOI=10.1042/bj20081668;
RA   Garcia-Martinez J.M., Alessi D.R.;
RT   "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and
RT   activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).";
RL   Biochem. J. 416:375-385(2008).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF IRS1, CATALYTIC ACTIVITY, FUNCTION IN
RP   GLUCOSE HOMEOSTASIS, AND INTERACTION WITH IRS1.
RX   PubMed=18952604; DOI=10.1074/jbc.m806480200;
RA   Zhang J., Gao Z., Yin J., Quon M.J., Ye J.;
RT   "S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance
RT   in response to TNF-(alpha) signaling through IKK2.";
RL   J. Biol. Chem. 283:35375-35382(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, ALTERNATIVE SPLICING, PHOSPHORYLATION AT
RP   SER-394; THR-412; THR-444 AND SER-447, AND SUBCELLULAR LOCATION.
RX   PubMed=19085255; DOI=10.1080/08977190802556986;
RA   Kim D., Akcakanat A., Singh G., Sharma C., Meric-Bernstam F.;
RT   "Regulation and localization of ribosomal protein S6 kinase 1 isoforms.";
RL   Growth Factors 27:12-21(2009).
RN   [23]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF THR-412.
RX   PubMed=19570988; DOI=10.1074/jbc.m109.032177;
RA   Keshwani M.M., Gao X., Harris T.K.;
RT   "Mechanism of PDK1-catalyzed Thr-229 phosphorylation of the S6K1 protein
RT   kinase.";
RL   J. Biol. Chem. 284:22611-22624(2009).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF RICTOR.
RX   PubMed=19720745; DOI=10.1128/mcb.00735-09;
RA   Dibble C.C., Asara J.M., Manning B.D.;
RT   "Characterization of Rictor phosphorylation sites reveals direct regulation
RT   of mTOR complex 2 by S6K1.";
RL   Mol. Cell. Biol. 29:5657-5670(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF RICTOR.
RX   PubMed=19995915; DOI=10.1128/mcb.00601-09;
RA   Julien L.A., Carriere A., Moreau J., Roux P.P.;
RT   "mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and
RT   regulates mTORC2 signaling.";
RL   Mol. Cell. Biol. 30:908-921(2010).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF RICTOR.
RX   PubMed=19935711; DOI=10.1038/onc.2009.401;
RA   Treins C., Warne P.H., Magnuson M.A., Pende M., Downward J.;
RT   "Rictor is a novel target of p70 S6 kinase-1.";
RL   Oncogene 29:1003-1016(2010).
RN   [28]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=18092230; DOI=10.1080/08977190701779101;
RA   Jastrzebski K., Hannan K.M., Tchoubrieva E.B., Hannan R.D., Pearson R.B.;
RT   "Coordinate regulation of ribosome biogenesis and function by the ribosomal
RT   protein S6 kinase, a key mediator of mTOR function.";
RL   Growth Factors 25:209-226(2007).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-441; THR-444; SER-447 AND
RP   SER-452, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=20932932; DOI=10.1016/j.biocel.2010.09.018;
RA   Fenton T.R., Gout I.T.;
RT   "Functions and regulation of the 70kDa ribosomal S6 kinases.";
RL   Int. J. Biochem. Cell Biol. 43:47-59(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-444 AND SER-447, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   FUNCTION, PHOSPHORYLATION OF CAD, AND PHOSPHORYLATION BY MTOR.
RX   PubMed=23429703; DOI=10.1126/science.1228792;
RA   Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.;
RT   "Stimulation of de novo pyrimidine synthesis by growth signaling through
RT   mTOR and S6K1.";
RL   Science 339:1323-1328(2013).
RN   [33]
RP   INTERACTION WITH IER5.
RX   PubMed=26496226; DOI=10.1016/j.febslet.2015.10.013;
RA   Kawabata S., Ishita Y., Ishikawa Y., Sakurai H.;
RT   "Immediate-early response 5 (IER5) interacts with protein phosphatase 2A
RT   and regulates the phosphorylation of ribosomal protein S6 kinase and heat
RT   shock factor 1.";
RL   FEBS Lett. 589:3679-3685(2015).
RN   [34]
RP   FUNCTION IN PHOSPHORYLATION OF EPRS, CATALYTIC ACTIVITY, AND ACTIVITY
RP   REGULATION.
RX   PubMed=28178239; DOI=10.1038/nature21380;
RA   Arif A., Terenzi F., Potdar A.A., Jia J., Sacks J., China A., Halawani D.,
RA   Vasu K., Li X., Brown J.M., Chen J., Kozma S.C., Thomas G., Fox P.L.;
RT   "EPRS is a critical mTORC1-S6K1 effector that influences adiposity in
RT   mice.";
RL   Nature 542:357-361(2017).
RN   [35]
RP   PHOSPHORYLATION AT THR-412.
RX   PubMed=29750193; DOI=10.1126/sciadv.aao5838;
RA   Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.;
RT   "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell
RT   proliferation and migration.";
RL   Sci. Adv. 4:EAAO5838-EAAO5838(2018).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 75-399, AND PHOSPHORYLATION AT
RP   THR-252.
RX   PubMed=19864428; DOI=10.1074/jbc.m109.040667;
RA   Sunami T., Byrne N., Diehl R.E., Funabashi K., Hall D.L., Ikuta M.,
RA   Patel S.B., Shipman J.M., Smith R.F., Takahashi I., Zugay-Murphy J.,
RA   Iwasawa Y., Lumb K.J., Munshi S.K., Sharma S.;
RT   "Structural basis of human p70 ribosomal S6 kinase-1 regulation by
RT   activation loop phosphorylation.";
RL   J. Biol. Chem. 285:4587-4594(2010).
RN   [37]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-289.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-225; CYS-272; CYS-276 AND ALA-398.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts downstream of mTOR
CC       signaling in response to growth factors and nutrients to promote cell
CC       proliferation, cell growth and cell cycle progression. Regulates
CC       protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and
CC       contributes to cell survival by repressing the pro-apoptotic function
CC       of BAD. Under conditions of nutrient depletion, the inactive form
CC       associates with the EIF3 translation initiation complex. Upon mitogenic
CC       stimulation, phosphorylation by the mammalian target of rapamycin
CC       complex 1 (mTORC1) leads to dissociation from the EIF3 complex and
CC       activation. The active form then phosphorylates and activates several
CC       substrates in the pre-initiation complex, including the EIF2B complex
CC       and the cap-binding complex component EIF4B. Also controls translation
CC       initiation by phosphorylating a negative regulator of EIF4A, PDCD4,
CC       targeting it for ubiquitination and subsequent proteolysis. Promotes
CC       initiation of the pioneer round of protein synthesis by phosphorylating
CC       POLDIP3/SKAR. In response to IGF1, activates translation elongation by
CC       phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and
CC       thus activation of EEF2. Also plays a role in feedback regulation of
CC       mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition
CC       of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating
CC       the pro-apoptotic protein BAD and suppressing its pro-apoptotic
CC       function. Phosphorylates mitochondrial URI1 leading to dissociation of
CC       a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then
CC       dephosphorylate RPS6KB1 at Thr-412, which is proposed to be a negative
CC       feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates
CC       TNF-alpha-induced insulin resistance by phosphorylating IRS1 at
CC       multiple serine residues, resulting in accelerated degradation of IRS1.
CC       In cells lacking functional TSC1-2 complex, constitutively
CC       phosphorylates and inhibits GSK3B. May be involved in cytoskeletal
CC       rearrangement through binding to neurabin. Phosphorylates and activates
CC       the pyrimidine biosynthesis enzyme CAD, downstream of MTOR
CC       (PubMed:11500364, PubMed:12801526, PubMed:14673156, PubMed:15071500,
CC       PubMed:15341740, PubMed:16286006, PubMed:17052453, PubMed:17053147,
CC       PubMed:17936702, PubMed:18952604, PubMed:19085255, PubMed:19720745,
CC       PubMed:19935711, PubMed:19995915, PubMed:23429703). Following
CC       activation by mTORC1, phosphorylates EPRS and thereby plays a key role
CC       in fatty acid uptake by adipocytes and also most probably in
CC       interferon-gamma-induced translation inhibition (PubMed:28178239).
CC       {ECO:0000269|PubMed:11500364, ECO:0000269|PubMed:12801526,
CC       ECO:0000269|PubMed:14673156, ECO:0000269|PubMed:15071500,
CC       ECO:0000269|PubMed:15341740, ECO:0000269|PubMed:16286006,
CC       ECO:0000269|PubMed:17052453, ECO:0000269|PubMed:17053147,
CC       ECO:0000269|PubMed:17936702, ECO:0000269|PubMed:18952604,
CC       ECO:0000269|PubMed:19085255, ECO:0000269|PubMed:19720745,
CC       ECO:0000269|PubMed:19935711, ECO:0000269|PubMed:19995915,
CC       ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:28178239}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:17936702, ECO:0000269|PubMed:18952604,
CC         ECO:0000269|PubMed:19085255, ECO:0000269|PubMed:28178239};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:17936702,
CC         ECO:0000269|PubMed:18952604, ECO:0000269|PubMed:19085255,
CC         ECO:0000269|PubMed:28178239};
CC   -!- ACTIVITY REGULATION: Activation requires multiple phosphorylation
CC       events on serine/threonine residues. Activation appears to be first
CC       mediated by phosphorylation of multiple sites in the autoinhibitory
CC       domain, which facilitates phosphorylation at Thr-412, disrupting the
CC       autoinhibitory mechanism and allowing phosphorylation of Thr-252 by
CC       PDPK1. The active conformation of the kinase is believed to be
CC       stabilized by a mechanism involving three conserved phosphorylation
CC       sites located in the kinase domain activation loop (Thr-252) and in the
CC       AGC-kinase C-terminal domain (Ser-394 in the middle of the tail/linker
CC       region and Thr-412 within a hydrophobic motif at its end). Activated by
CC       mTORC1; isoform Alpha I and isoform Alpha II are sensitive to
CC       rapamycin, which inhibits activating phosphorylation at Thr-412.
CC       Activated by PDPK1. {ECO:0000269|PubMed:17446865,
CC       ECO:0000269|PubMed:19570988, ECO:0000269|PubMed:28178239,
CC       ECO:0000269|PubMed:9445476}.
CC   -!- SUBUNIT: Interacts with PPP1R9A/neurabin-1 (By similarity). Interacts
CC       with RPTOR (PubMed:12150926). Interacts with IRS1 (PubMed:18952604).
CC       Interacts with EIF3B and EIF3C (PubMed:16286006). Interacts with TRAF4
CC       (PubMed:12801526). Interacts with POLDIP3 (PubMed:15341740). Interacts
CC       (via N-terminus) with IER5 (PubMed:26496226).
CC       {ECO:0000250|UniProtKB:P67999, ECO:0000269|PubMed:12150926,
CC       ECO:0000269|PubMed:12801526, ECO:0000269|PubMed:15341740,
CC       ECO:0000269|PubMed:16286006, ECO:0000269|PubMed:18952604,
CC       ECO:0000269|PubMed:26496226}.
CC   -!- INTERACTION:
CC       P23443; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1775921, EBI-25646567;
CC       P23443; P55884: EIF3B; NbExp=3; IntAct=EBI-1775921, EBI-366696;
CC       P23443; P08151: GLI1; NbExp=4; IntAct=EBI-1775921, EBI-308084;
CC       P23443; Q5VY09: IER5; NbExp=2; IntAct=EBI-1775921, EBI-1774000;
CC       P23443; Q00005: PPP2R2B; NbExp=2; IntAct=EBI-1775921, EBI-1052159;
CC       P23443; P13051-2: UNG; NbExp=3; IntAct=EBI-1775921, EBI-25834258;
CC       P23443-2; P08151: GLI1; NbExp=2; IntAct=EBI-6093204, EBI-308084;
CC       P23443-4; P05067: APP; NbExp=3; IntAct=EBI-25882353, EBI-77613;
CC       P23443-4; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-25882353, EBI-9090282;
CC   -!- SUBCELLULAR LOCATION: Synapse, synaptosome {ECO:0000250}. Mitochondrion
CC       outer membrane. Mitochondrion. Note=Colocalizes with URI1 at
CC       mitochondrion.
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha I]: Nucleus. Cytoplasm.
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha II]: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Alpha I; Synonyms=p80-S6K 1;
CC         IsoId=P23443-1; Sequence=Displayed;
CC       Name=Alpha II;
CC         IsoId=P23443-2; Sequence=VSP_018839;
CC       Name=2;
CC         IsoId=P23443-3; Sequence=VSP_054613;
CC       Name=4;
CC         IsoId=P23443-5; Sequence=VSP_055026;
CC       Name=3;
CC         IsoId=P23443-4; Sequence=VSP_054614;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:9804755}.
CC   -!- DOMAIN: The autoinhibitory domain is believed to block phosphorylation
CC       within the AGC-kinase C-terminal domain and the activation loop.
CC   -!- DOMAIN: The TOS (TOR signaling) motif is essential for activation by
CC       mTORC1. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Thr-412 is regulated by mTORC1. The
CC       phosphorylation at this site is maintained by an agonist-dependent
CC       autophosphorylation mechanism (By similarity). Activated by
CC       phosphorylation at Thr-252 by PDPK1. Dephosphorylation by PPP1CC at
CC       Thr-412 in mitochondrion. {ECO:0000250, ECO:0000269|PubMed:18925875,
CC       ECO:0000269|PubMed:19085255, ECO:0000269|PubMed:19864428,
CC       ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:9445476}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. S6 kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M60724; AAA36410.1; -; mRNA.
DR   EMBL; M60725; AAA36411.1; -; mRNA.
DR   EMBL; AK297147; BAG59646.1; -; mRNA.
DR   EMBL; AK300202; BAG61973.1; -; mRNA.
DR   EMBL; AK312875; BAG35726.1; -; mRNA.
DR   EMBL; AC004686; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471109; EAW94384.1; -; Genomic_DNA.
DR   EMBL; BC053365; AAH53365.1; -; mRNA.
DR   CCDS; CCDS11621.1; -. [P23443-1]
DR   CCDS; CCDS62271.1; -. [P23443-4]
DR   CCDS; CCDS62272.1; -. [P23443-5]
DR   CCDS; CCDS62273.1; -. [P23443-3]
DR   PIR; A41687; A41687.
DR   RefSeq; NP_001258971.1; NM_001272042.1. [P23443-5]
DR   RefSeq; NP_001258972.1; NM_001272043.1. [P23443-4]
DR   RefSeq; NP_001258973.1; NM_001272044.1. [P23443-3]
DR   RefSeq; NP_001258989.1; NM_001272060.1. [P23443-2]
DR   RefSeq; NP_003152.1; NM_003161.3. [P23443-1]
DR   PDB; 3A60; X-ray; 2.80 A; A/B=75-399.
DR   PDB; 3A61; X-ray; 3.43 A; A=75-399.
DR   PDB; 3A62; X-ray; 2.35 A; A=75-399.
DR   PDB; 3WE4; X-ray; 2.00 A; A=78-399.
DR   PDB; 3WF5; X-ray; 2.10 A; A=78-399.
DR   PDB; 3WF6; X-ray; 2.03 A; A=78-399.
DR   PDB; 3WF7; X-ray; 1.85 A; A=78-399.
DR   PDB; 3WF8; X-ray; 1.98 A; A=78-399.
DR   PDB; 3WF9; X-ray; 2.04 A; A=78-399.
DR   PDB; 4L3J; X-ray; 2.10 A; A=75-375.
DR   PDB; 4L3L; X-ray; 2.10 A; A=75-375.
DR   PDB; 4L42; X-ray; 2.80 A; A=75-417.
DR   PDB; 4L43; X-ray; 3.00 A; A=75-417.
DR   PDB; 4L44; X-ray; 2.90 A; A=75-417.
DR   PDB; 4L45; X-ray; 2.90 A; A=75-417.
DR   PDB; 4L46; X-ray; 3.01 A; A=75-417.
DR   PDB; 4RLO; X-ray; 2.53 A; A/B=85-372.
DR   PDB; 4RLP; X-ray; 2.79 A; A=85-372.
DR   PDB; 5WBH; X-ray; 1.75 A; W=412-437.
DR   PDB; 5WBK; X-ray; 3.11 A; T=24-37.
DR   PDBsum; 3A60; -.
DR   PDBsum; 3A61; -.
DR   PDBsum; 3A62; -.
DR   PDBsum; 3WE4; -.
DR   PDBsum; 3WF5; -.
DR   PDBsum; 3WF6; -.
DR   PDBsum; 3WF7; -.
DR   PDBsum; 3WF8; -.
DR   PDBsum; 3WF9; -.
DR   PDBsum; 4L3J; -.
DR   PDBsum; 4L3L; -.
DR   PDBsum; 4L42; -.
DR   PDBsum; 4L43; -.
DR   PDBsum; 4L44; -.
DR   PDBsum; 4L45; -.
DR   PDBsum; 4L46; -.
DR   PDBsum; 4RLO; -.
DR   PDBsum; 4RLP; -.
DR   PDBsum; 5WBH; -.
DR   PDBsum; 5WBK; -.
DR   AlphaFoldDB; P23443; -.
DR   SMR; P23443; -.
DR   BioGRID; 112112; 87.
DR   DIP; DIP-29986N; -.
DR   ELM; P23443; -.
DR   IntAct; P23443; 36.
DR   MINT; P23443; -.
DR   STRING; 9606.ENSP00000225577; -.
DR   BindingDB; P23443; -.
DR   ChEMBL; CHEMBL4501; -.
DR   DrugCentral; P23443; -.
DR   GuidetoPHARMACOLOGY; 1525; -.
DR   iPTMnet; P23443; -.
DR   PhosphoSitePlus; P23443; -.
DR   BioMuta; RPS6KB1; -.
DR   DMDM; 54041234; -.
DR   EPD; P23443; -.
DR   jPOST; P23443; -.
DR   MassIVE; P23443; -.
DR   MaxQB; P23443; -.
DR   PaxDb; P23443; -.
DR   PeptideAtlas; P23443; -.
DR   PRIDE; P23443; -.
DR   ProteomicsDB; 28050; -.
DR   ProteomicsDB; 4559; -.
DR   ProteomicsDB; 54095; -. [P23443-1]
DR   ProteomicsDB; 54096; -. [P23443-2]
DR   ProteomicsDB; 69478; -.
DR   Antibodypedia; 3544; 2663 antibodies from 53 providers.
DR   DNASU; 6198; -.
DR   Ensembl; ENST00000225577.9; ENSP00000225577.4; ENSG00000108443.14. [P23443-1]
DR   Ensembl; ENST00000393021.7; ENSP00000376744.3; ENSG00000108443.14. [P23443-3]
DR   Ensembl; ENST00000406116.7; ENSP00000384335.3; ENSG00000108443.14. [P23443-4]
DR   Ensembl; ENST00000443572.6; ENSP00000441993.1; ENSG00000108443.14. [P23443-5]
DR   GeneID; 6198; -.
DR   KEGG; hsa:6198; -.
DR   MANE-Select; ENST00000225577.9; ENSP00000225577.4; NM_003161.4; NP_003152.1.
DR   UCSC; uc002ixy.5; human. [P23443-1]
DR   CTD; 6198; -.
DR   DisGeNET; 6198; -.
DR   GeneCards; RPS6KB1; -.
DR   HGNC; HGNC:10436; RPS6KB1.
DR   HPA; ENSG00000108443; Low tissue specificity.
DR   MIM; 608938; gene.
DR   neXtProt; NX_P23443; -.
DR   OpenTargets; ENSG00000108443; -.
DR   PharmGKB; PA34851; -.
DR   VEuPathDB; HostDB:ENSG00000108443; -.
DR   eggNOG; KOG0598; Eukaryota.
DR   GeneTree; ENSGT00940000154203; -.
DR   HOGENOM; CLU_000288_63_5_1; -.
DR   InParanoid; P23443; -.
DR   OMA; KGSIFAM; -.
DR   OrthoDB; 1132245at2759; -.
DR   PhylomeDB; P23443; -.
DR   TreeFam; TF313438; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P23443; -.
DR   Reactome; R-HSA-166208; mTORC1-mediated signalling.
DR   SABIO-RK; P23443; -.
DR   SignaLink; P23443; -.
DR   SIGNOR; P23443; -.
DR   BioGRID-ORCS; 6198; 40 hits in 1116 CRISPR screens.
DR   ChiTaRS; RPS6KB1; human.
DR   EvolutionaryTrace; P23443; -.
DR   GeneWiki; P70-S6_Kinase_1; -.
DR   GenomeRNAi; 6198; -.
DR   Pharos; P23443; Tchem.
DR   PRO; PR:P23443; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P23443; protein.
DR   Bgee; ENSG00000108443; Expressed in endothelial cell and 189 other tissues.
DR   ExpressionAtlas; P23443; baseline and differential.
DR   Genevisible; P23443; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0030165; F:PDZ domain binding; IEA:Ensembl.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IEA:Ensembl.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004711; F:ribosomal protein S6 kinase activity; IBA:GO_Central.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0001662; P:behavioral fear response; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0044539; P:long-chain fatty acid import into cell; ISS:UniProtKB.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0048633; P:positive regulation of skeletal muscle tissue growth; IEA:Ensembl.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB.
DR   GO; GO:0045948; P:positive regulation of translational initiation; IMP:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0046324; P:regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0014878; P:response to electrical stimulus involved in regulation of muscle adaptation; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0033762; P:response to glucagon; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0043201; P:response to leucine; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0014732; P:skeletal muscle atrophy; IEA:Ensembl.
DR   GO; GO:0003009; P:skeletal muscle contraction; IEA:Ensembl.
DR   GO; GO:0031929; P:TOR signaling; IDA:UniProtKB.
DR   DisProt; DP01554; -.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016238; Ribosomal_S6_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000605; Ribsml_S6_kin_1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Alternative splicing;
KW   Apoptosis; ATP-binding; Cell cycle; Cytoplasm; Kinase; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Synapse; Synaptosome; Transferase; Translation regulation.
FT   CHAIN           1..525
FT                   /note="Ribosomal protein S6 kinase beta-1"
FT                   /id="PRO_0000024342"
FT   DOMAIN          91..352
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          353..423
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          1..54
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          380..399
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          424..525
FT                   /note="Autoinhibitory domain"
FT   MOTIF           28..32
FT                   /note="TOS motif"
FT   COMPBIAS        8..26
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        27..48
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        218
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         97..105
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         123
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         252
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:19864428,
FT                   ECO:0000269|PubMed:9445476"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19085255"
FT   MOD_RES         412
FT                   /note="Phosphothreonine; by MTOR, NEK6 and NEK7"
FT                   /evidence="ECO:0000269|PubMed:29750193"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P67999"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         444
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:19085255,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19085255,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         516
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P67999"
FT   VAR_SEQ         1..53
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054613"
FT   VAR_SEQ         1..23
FT                   /note="Missing (in isoform Alpha II)"
FT                   /evidence="ECO:0000303|PubMed:1922062"
FT                   /id="VSP_018839"
FT   VAR_SEQ         104..126
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055026"
FT   VAR_SEQ         448..525
FT                   /note="PVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIR
FT                   QPNSGPYKKQAFPMISKRPEHLRMNL -> TAMC (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054614"
FT   VARIANT         225
FT                   /note="M -> I"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040639"
FT   VARIANT         272
FT                   /note="R -> C (in dbSNP:rs766645749)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040640"
FT   VARIANT         276
FT                   /note="W -> C"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040641"
FT   VARIANT         289
FT                   /note="G -> E (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035628"
FT   VARIANT         398
FT                   /note="S -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040642"
FT   MUTAGEN         167
FT                   /note="K->N: Greatly reduces activity. Greatly reduces
FT                   phosphorylation at T-412 and moderately reduces
FT                   phosphorylation at T-252."
FT                   /evidence="ECO:0000269|PubMed:17446865"
FT   MUTAGEN         394
FT                   /note="S->A: Loss of activity. Loss of phosphorylation at
FT                   T-412."
FT                   /evidence="ECO:0000269|PubMed:17446865"
FT   MUTAGEN         412
FT                   /note="T->E: Mimics phosphorylation. Facilitates
FT                   phosphorylation of T-252 by PDPK1; when associated with
FT                   E-434; E-441; E-444 and E-447. Mimics phosphorylation. No
FT                   effect on interaction with PDPK1 and phosphorylation of
FT                   T-252. Impairs association with the eIF3 complex."
FT                   /evidence="ECO:0000269|PubMed:16286006,
FT                   ECO:0000269|PubMed:19570988, ECO:0000269|PubMed:9445476"
FT   MUTAGEN         434
FT                   /note="S->E: Facilitates phosphorylation of T-252 by PDPK1;
FT                   when associated with E-412; E-441; E-444 and E-447."
FT                   /evidence="ECO:0000269|PubMed:9445476"
FT   MUTAGEN         441
FT                   /note="S->E: Facilitates phosphorylation of T-252 by PDPK1;
FT                   when associated with E-412; E-434; E-444 and E-447."
FT                   /evidence="ECO:0000269|PubMed:9445476"
FT   MUTAGEN         444
FT                   /note="T->E: Facilitates phosphorylation of T-252 by PDPK1;
FT                   when associated with E-412; E-434; E-441 and E-447."
FT                   /evidence="ECO:0000269|PubMed:9445476"
FT   MUTAGEN         447
FT                   /note="S->E: Facilitates phosphorylation of T-252 by PDPK1;
FT                   when associated with E-412; E-434; E-441 and E-444."
FT                   /evidence="ECO:0000269|PubMed:9445476"
FT   CONFLICT        222
FT                   /note="E -> V (in Ref. 2; BAG61973)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        428
FT                   /note="F -> L (in Ref. 2; BAG35726)"
FT                   /evidence="ECO:0000305"
FT   HELIX           88..90
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          91..99
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          101..110
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   TURN            114..117
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          119..126
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           127..132
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           137..149
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          158..164
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          167..173
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           180..187
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           192..212
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           221..223
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          224..226
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          232..234
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          246..249
FT                   /evidence="ECO:0007829|PDB:3WF8"
FT   STRAND          252..255
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           262..265
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   TURN            266..269
FT                   /evidence="ECO:0007829|PDB:4RLO"
FT   HELIX           273..288
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           298..307
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          314..316
FT                   /evidence="ECO:0007829|PDB:3A61"
FT   HELIX           318..327
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           332..334
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   TURN            340..342
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           343..347
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   HELIX           357..361
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   TURN            371..373
FT                   /evidence="ECO:0007829|PDB:3WF7"
FT   STRAND          374..377
FT                   /evidence="ECO:0007829|PDB:4L44"
FT   TURN            380..382
FT                   /evidence="ECO:0007829|PDB:4L45"
FT   HELIX           409..411
FT                   /evidence="ECO:0007829|PDB:4L42"
FT   STRAND          413..415
FT                   /evidence="ECO:0007829|PDB:4L42"
FT   HELIX           418..421
FT                   /evidence="ECO:0007829|PDB:5WBH"
FT   HELIX           423..426
FT                   /evidence="ECO:0007829|PDB:5WBH"
FT   HELIX           429..431
FT                   /evidence="ECO:0007829|PDB:5WBH"
SQ   SEQUENCE   525 AA;  59140 MW;  2C3BA13CCDAF4AB3 CRC64;
     MRRRRRRDGF YPAPDFRDRE AEDMAGVFDI DLDQPEDAGS EDELEEGGQL NESMDHGGVG
     PYELGMEHCE KFEISETSVN RGPEKIRPEC FELLRVLGKG GYGKVFQVRK VTGANTGKIF
     AMKVLKKAMI VRNAKDTAHT KAERNILEEV KHPFIVDLIY AFQTGGKLYL ILEYLSGGEL
     FMQLEREGIF MEDTACFYLA EISMALGHLH QKGIIYRDLK PENIMLNHQG HVKLTDFGLC
     KESIHDGTVT HTFCGTIEYM APEILMRSGH NRAVDWWSLG ALMYDMLTGA PPFTGENRKK
     TIDKILKCKL NLPPYLTQEA RDLLKKLLKR NAASRLGAGP GDAGEVQAHP FFRHINWEEL
     LARKVEPPFK PLLQSEEDVS QFDSKFTRQT PVDSPDDSTL SESANQVFLG FTYVAPSVLE
     SVKEKFSFEP KIRSPRRFIG SPRTPVSPVK FSPGDFWGRG ASASTANPQT PVEYPMETSG
     IEQMDVTMSG EASAPLPIRQ PNSGPYKKQA FPMISKRPEH LRMNL
//
